

## **Webinar Summary:** [Promoting Diversity in Clinical Trials \[May 1, 2024\]](#)

This document summarizes recommendations and action items brought forward by speakers at the Health Research Alliance DEI Learning Community Call on May 1, 2024.

### **Speakers:**

Barbara Bierer, MD

*Professor of Medicine, Harvard Medical School*

*Co-Founder, Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard*

Alice Kuaban, MS

*Deputy Director, Scientific Affairs, American Society of Hematology*

Patricia Hurley, MSc

*Senior Director, Strategic Research Initiatives, American Society of Clinical Oncology*

### **Possible Roles and Actions:**

#### [Barbara Bierer's Slides:](#)

##### Public Awareness and Communication

- Provide access to information to patients, potential participants, and communities
  - About their rights as research volunteers
  - About clinical trials in general
  - About disease-specific possible trials
- Provide and align patient and participant navigators
- Plan and support community health and health research activities

##### Workforce Diversity

- Intentionality: Funding students, trainees, and others from diverse backgrounds
- Supplemental awards for people who represent underserved communities
- Engage in and/or fund health fairs for the recruitment of future workforce
- Create (direct) or Fund (indirect) honorific awards, microgrants, training, internships

##### Equitable Access to Trial Participation

- Require diversity action plans
- Create (direct) or Fund (indirect) community advisory board review
- Require payment to patient partners as a condition of service
- Enable participant navigators
- Require plain language review of materials, user testing by patients/patient advocates
- Recommend or require translation and interpreter services
- Require accommodations
- Require reimbursement and compensation and allow incentive payments
- Provide advice on tax and means-tested eligibility implications
- Require (fund) or provide transportation

- Digital enablement
- Return of results (individual and aggregate data) to participants and the communities they represent

#### Comprehensive and Consistent Data

- Collect, aggregate, and provide data
  - Epidemiology of the disease or condition, by demographic variable
  - Common data elements and standards
  - Fund development of standards and data sharing
- As a condition of grant award:
  - Recommend data standards
  - Require data dictionary and data sharing

#### Accountability

- Self-assessment of current state within nonprofit funding organizations
- Diverse representation on board of directors, standing committees
- Review of, and metrics to inform, grant portfolio
- Bias training and cultural sensitivity training of defined populations

#### [Alice Kuaban's Slides:](#)

- Examine Inclusion/Exclusion Criteria: For rare disease, determinations about trial inclusion/exclusion criteria must be evaluated early to determine implications on diversity, accessibility, and alignment with real-world results
- Decentralized Clinical Trial options can enhance access
- Institutional Review Boards have a role to play in enhancing diversity in clinical trials
- Global standardization of definitions regarding diversity and inclusivity in clinical research are needed
- Action examples from ASH:
  - Developing [DEI Toolkit for Clinical Trial Sponsors](#)
  - Creating a learning ecosystem so clinical trialists can learn and share how to build inclusive clinical trials
  - Creating education resources and programs to support workforce development (e.g., ASH Clinical Research Training Institute includes DEI principles as part of study design curriculum)
  - Request for demographic information (sex, gender, race, ethnicity, age, disability, other relevant factors of enrolled subjects) to be submitted for individuals submitting/presenting on clinical studies (ASH Events, ASH publications). If demographics are NOT available, the investigator will be asked to describe the limitations that prevented these data from being collected.

#### [Patricia Hurley's Slides:](#)

- [Graphic](#) summarizing recommendations from the article "[Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement](#)"

- Prepare research sites and networks to improve EDI in clinical research
  - [Research site self-assessment](#): Enable internal review of policies, programs, procedures to identify opportunities for improvement
  - [Just ASK™ Increasing Diversity in Cancer Clinical Research: An ACCC-ASCO Training Program](#) and companion [Facilitation Guide](#) - Implicit bias training program for clinicians and staff to assess and mitigate biases regarding who is screened for and offered clinical trials
  - Detailed list of resources for clinical trial sites (and other groups):  
<https://society.asco.org/sites/new-www.asco.org/files/content-files/news-initiatives/documents/ASCO-ACCC-EDI-Clinical-Trial-Resources-May-2022.xlsx>
- [Broaden eligibility criteria](#) and [geographic access to trials](#)
- Operationalize decentralized clinical trials
  - Clarify FDA Form 1572 requirements to ensure consistent interpretation
  - Advocate for routine acceptance of local laboratory and imaging facilities
  - Foster partnerships to increase patient and local clinician access to trials